[
  {
    "ts": null,
    "headline": "Fidelity Balanced Fund Q2 2025 Commentary",
    "summary": "Fidelity Investments reports a 2.74% Q1 loss for its Balanced Fund. See how equity picks and bond strategy shaped results. Review the full update.",
    "url": "https://finnhub.io/api/news?id=a8c74b2643fa75761f001aefff25b82d418a05756262be856f32dae651db4c17",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753476000,
      "headline": "Fidelity Balanced Fund Q2 2025 Commentary",
      "id": 136092560,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1383095217/image_1383095217.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Fidelity Investments reports a 2.74% Q1 loss for its Balanced Fund. See how equity picks and bond strategy shaped results. Review the full update.",
      "url": "https://finnhub.io/api/news?id=a8c74b2643fa75761f001aefff25b82d418a05756262be856f32dae651db4c17"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences (GILD) Stock Is Up Today",
    "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval from a key European regulatory committee.",
    "url": "https://finnhub.io/api/news?id=d0c647f5ee46f7133eab1a6b79564587aaa25ea48587074821828a2a683f39d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753469467,
      "headline": "Why Gilead Sciences (GILD) Stock Is Up Today",
      "id": 136090900,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval from a key European regulatory committee.",
      "url": "https://finnhub.io/api/news?id=d0c647f5ee46f7133eab1a6b79564587aaa25ea48587074821828a2a683f39d0"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences Stock Just Popped",
    "summary": "Gilead stock is flashing \"buy\" in bright green letters.",
    "url": "https://finnhub.io/api/news?id=aec7b4e8c29973507382e67689371035d1d944b1a2680410a225a11e43a280c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753465069,
      "headline": "Why Gilead Sciences Stock Just Popped",
      "id": 136090901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead stock is flashing \"buy\" in bright green letters.",
      "url": "https://finnhub.io/api/news?id=aec7b4e8c29973507382e67689371035d1d944b1a2680410a225a11e43a280c7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=00941ac4cabe176ae5d1ac950e4aa73cbe88a8597376c633080b44eff08b4729",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753461420,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 136123209,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=00941ac4cabe176ae5d1ac950e4aa73cbe88a8597376c633080b44eff08b4729"
    }
  },
  {
    "ts": null,
    "headline": "Solid Corporate Earnings Results Support Stocks",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.19%. September E-mini S&P futures (ESU25 ) are up +0.18%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=fc0cb8e0bb2a3e289db4043df58d2d3f3d3908fc9c1b7d6e89d0b6048d1c458a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753456329,
      "headline": "Solid Corporate Earnings Results Support Stocks",
      "id": 136088573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.19%. September E-mini S&P futures (ESU25 ) are up +0.18%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=fc0cb8e0bb2a3e289db4043df58d2d3f3d3908fc9c1b7d6e89d0b6048d1c458a"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Gilead Sciences (GILD) is a Strong Value Stock",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=2f755367bd750e7d532b95bddbc6c84ba706af4a0b73334ee5943409e220fafa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753450802,
      "headline": "Here's Why Gilead Sciences (GILD) is a Strong Value Stock",
      "id": 136088695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=2f755367bd750e7d532b95bddbc6c84ba706af4a0b73334ee5943409e220fafa"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention",
    "summary": "FOSTER CITY, Calif., July 25, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company’s injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final European Commission",
    "url": "https://finnhub.io/api/news?id=d09d4cbf27d4370aa5bbf493a283d19c2a49f4b265285fa2e307074569c10ab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753426800,
      "headline": "Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention",
      "id": 136085102,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., July 25, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company’s injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final European Commission",
      "url": "https://finnhub.io/api/news?id=d09d4cbf27d4370aa5bbf493a283d19c2a49f4b265285fa2e307074569c10ab9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Gets CHMP Backing for Twice-Yearly Treatment to Prevent HIV",
    "summary": "Gilead Gets CHMP Backing for Twice-Yearly Treatment to Prevent HIV",
    "url": "https://finnhub.io/api/news?id=1dc04704e91d5b4d008dca8d5c8b996febcbf177ce9f822008b95865b91ea06d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753423740,
      "headline": "Gilead Gets CHMP Backing for Twice-Yearly Treatment to Prevent HIV",
      "id": 136123210,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Gets CHMP Backing for Twice-Yearly Treatment to Prevent HIV",
      "url": "https://finnhub.io/api/news?id=1dc04704e91d5b4d008dca8d5c8b996febcbf177ce9f822008b95865b91ea06d"
    }
  },
  {
    "ts": null,
    "headline": "Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial",
    "summary": "Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid assembly modulator for the treatment of chronic hepatitis B. The 28-day study showed HBV DNA reductions of 2.9 log10 IU/mL at 150 […]",
    "url": "https://finnhub.io/api/news?id=c55e4f65847c0686335bb73ec68952e305a8402faf7da5c713b65965e540c759",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753415286,
      "headline": "Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial",
      "id": 136085103,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid assembly modulator for the treatment of chronic hepatitis B. The 28-day study showed HBV DNA reductions of 2.9 log10 IU/mL at 150 […]",
      "url": "https://finnhub.io/api/news?id=c55e4f65847c0686335bb73ec68952e305a8402faf7da5c713b65965e540c759"
    }
  }
]